StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Gyre Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 93.4%. For fiscal 2025 it was 95.4%, against 96.3% the year before. The highest annual figure on record is 97.2% in fiscal 2009.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202595.4%−1.0
FY2024Dec 31, 202496.3%+0.4
FY2023Dec 31, 202395.9%+0.6
FY2022Dec 31, 202295.3%−1.9
FY2009Dec 31, 200997.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202694.1%+5.6
Q2 FY2026Jun 30, 202692.4%+6.2
Q1 FY2026Mar 31, 202694.6%−1.4
Q4 FY2025Dec 31, 202592.6%−3.2
Q3 FY2025Sep 30, 202588.5%−7.7
Q2 FY2025Jun 30, 202586.2%−10.8
Q1 FY2025Mar 31, 202595.9%−0.4
Q4 FY2024Dec 31, 202495.8%+0.4
Q3 FY2024Sep 30, 202496.2%−0.1
Q2 FY2024Jun 30, 202496.9%+0.6
Q1 FY2024Mar 31, 202496.4%+0.9
Q4 FY2023Dec 31, 202395.4%–
Q3 FY2023Sep 30, 202396.3%–
Q2 FY2023Jun 30, 202396.3%–
Q1 FY2023Mar 31, 202395.5%–

More Gyre Therapeutics figures

See a number that looks wrong?